The company’s PhD research focused on using lasers for precise intracellular cargo delivery. However, conversations with 100+ industry experts revealed a more critical, and technically simpler, problem in cell therapy manufacturing: removing unwanted cells. This demonstrates the value of prioritizing market needs over scientific complexity.

The company's technology is a delivery system. By containing potent compounds within the tumor via direct injection, it can make previously shelved drugs—those too toxic for systemic use—viable therapies, creating a new pipeline of cancer treatments.

The company's buffering agent is naturally drawn to the most acidic areas of the body. Since tumors actively export acid, they create a "magnet" for the therapy. This approach leverages basic chemical kinetics for targeting, bypassing the need for complex biological receptors and acting as an upstream solution.

For decades, tumor acidity was considered a mere consequence of metabolic activity (the Warburg effect). The modern understanding underpinning Dive’s strategy is that this acidity is a causal factor that actively drives tumor invasion, treatment resistance, and immune suppression, making it a viable therapeutic target.

Many biotechs start with a single technology to solve a single problem. Dispatch Bio's co-founders believed a superior company could be created with a suite of technologies that addresses numerous field observations at once, creating a more robust therapeutic platform.

Instead of going directly into high-risk oncology trials, Dive validated its core mechanism—systemic pH modulation via a topical agent—in a 98-patient gout study. This provided human data on target engagement and safety, significantly de-risking its subsequent, more complex cancer program by answering a key question upfront.

While most immuno-oncology drugs target specific cellular pathways, Dive Biosciences targets the acidic tumor microenvironment itself. This is framed as a foundational "upstream checkpoint" that degrades the entire immune "ecology," suppressing every type of immune cell in the tumor's vicinity at once, rather than one receptor at a time.

Previous human trials using oral sodium bicarbonate to buffer tumor acidity failed not because the biology was wrong, but because patients couldn't tolerate the required doses, leading to GI issues and non-adherence. Dive's transdermal approach bypasses the gut, solving a simple delivery challenge for a well-established biological target.

The company's lead molecule was initially invented to treat CNS diseases like Alzheimer's. A pivot occurred when a postdoc with an interest in oncology tested the compounds against refractory tumors, uncovering their true potential and leading to the company's formation around a new indication.